Pfizer Inc. Files 8-K: Board and Executive Compensation Updates

Ticker: PFE · Form: 8-K · Filed: 2024-10-15T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, executive-compensation, board-of-directors

Related Tickers: PFE

TL;DR

Pfizer's 8-K: New directors elected, exec pay changes. Stay tuned.

AI Summary

On October 10, 2024, Pfizer Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing includes information on the election of new directors and updates to compensatory arrangements for certain officers. Specific details regarding the financial impact or new appointments are not elaborated in this summary section of the filing.

Why It Matters

This filing signals potential shifts in corporate governance and executive incentives at Pfizer, which could influence strategic decisions and shareholder value.

Risk Assessment

Risk Level: low — The filing primarily concerns routine corporate governance updates and executive compensation, which typically carry a low immediate risk to the company's operations.

Key Numbers

Key Players & Entities

FAQ

What specific changes were made to Pfizer's board of directors?

The filing indicates the election of directors but does not specify the names of newly elected directors or any departures in this section.

Are there any details on the new compensatory arrangements for officers?

The filing mentions updates to compensatory arrangements for certain officers, but the specific details of these arrangements are not provided in this summary.

What is the significance of the 'Departure of Directors or Certain Officers' item?

This item signifies that there have been changes related to the company's directors or key officers, which could include resignations, terminations, or other departures.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on October 10, 2024.

What is Pfizer's state of incorporation and fiscal year end?

Pfizer Inc. is incorporated in Delaware and its fiscal year ends on December 31.

From the Filing

0000078003-24-000185.txt : 20241015 0000078003-24-000185.hdr.sgml : 20241015 20241015071826 ACCESSION NUMBER: 0000078003-24-000185 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20241010 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241015 DATE AS OF CHANGE: 20241015 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PFIZER INC CENTRAL INDEX KEY: 0000078003 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 135315170 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-03619 FILM NUMBER: 241369249 BUSINESS ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 BUSINESS PHONE: 2127332323 MAIL ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 FORMER COMPANY: FORMER CONFORMED NAME: PFIZER CHARLES & CO INC DATE OF NAME CHANGE: 19710908 8-K 1 pfe-20241010.htm PFIZER 8-K OCTOBER 10 2024 pfe-20241010 0000078003 false 0000078003 2024-10-10 2024-10-10 0000078003 us-gaap:CommonStockMember 2024-10-10 2024-10-10 0000078003 pfe:NotesDue20271.000Member 2024-10-10 2024-10-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.  20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 10, 2024 PFIZER INC . (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other (Commission File (I.R.S. Employer jurisdiction of Number) Identification No.) incorporation)     66 Hudson Boulevard East 10001-2192 New York, New York (Zip Code) (Address of principal executive offices) Registrant’s telephone number, including area code: ( 212 ) 733-2323 (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $.05 par value PFE New York Stock Exchange 1.000% Notes due 2027 PFE27 New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company     ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Election of Mr. Buckley to the Board of Directors On October 10, 2024, the Board of Directors (the “Board”) of Pfizer Inc. (the “Company”) elected Mortimer J. Buckley to serve as a member of the Company’s Board, effective immediately. In addition, he was el

View on Read The Filing